Japan Society of Gene and Cell Therapy

[OP-1]Opening Remarks

[CL-1]Current Status and Details of Gene and Cell Therapy

^○RYUICHI MORISHITA(Osaka University)

[SL1-1]コロナ禍乗り越え、新たな時代に

^○Katsunobu Kato(Minister of Health, Labour and Welfare)

[SL2-1]OMNITM Triple-platform technology - Removing the barriers in CRISPR-based gene editing therapy

^○David Baram¹, Liat Rockah¹, Milit Marom¹, Shira Warszawski¹, Nir Hecht¹, Nir Shpak¹, Rivkah Rogawski¹, Shir Weber¹, Veronica Moskovicz¹, Bar Dagan¹, Tami Khazma¹, Maya Noff¹, Nir Shahar¹, Dotan Omer¹, Roy Sirkis¹, David C. Dale², Asael Herman¹, Rafi Emmanuel¹, Lior Izhar¹(1.EmendoBio, Inc., New York, USA, 2.Department of Medicine, University of Washington, Seattle, WA, USA)

[DI-1]対談セッション

^○Takenori Emoto(Former member of the House of Representatives)

[SP1-1]Gene therapy technologies to be expected by global pharma in the future

^○Yasushi Kajii¹(1.Takeda Pharmaceutical Company Limited, 2.Waseda University)

[SP1-2]Genome editing technology innovation : from Japan to Global

^○Tomoji Mashimo¹(1.The University of Tokyo, Institute of Medical Science,, 2.C4U Corporation)

[SP1-3]TBD

^○Takeshi Takahashi(Catalys Pacific)

[SP1-4]Building ecosystem to accelerate commercialization of innovative technology

^○Toshio Fujimoto(iPark Institute, Co. Ltd.)

[SP2-1]MEXT’s R&D promotion for regenerative medicine and cell and gene therapy

^○Hiroyuki Kamai(Ministry of education)

[SP2-2]Amendment of the Act of the Safety of Regenerative Medicine related to in vivo gene therapy

^○Keigo Sano(Office for Promotion of Regenerative Medicine, Research and Development Policy Division, Health Policy Bureau, Ministry of Health, Labour and Welfare)

[SP2-3]Our current status and future support measures for the industrialization of the gene therapy field

^○Hirokazu Shimoda(Bio-Industry Division, Commerce and Service Industry Policy Group, METI)

[SP2-4]TBD

^○Kentaro Ohki(Japan Agency for Medical Research and Development)

[SP3-1]Forefront of critical care by regenrative medicine　　～Treatment strategies for extensive burns using autologus cultured epidermis

^○Takahiro Ueda(Tottori University Faculty of Medicine)

[SP3-2]Utilization Experience of JACC?: Advancing Cartilage Injury Treatment in the Knee Joint

^○Yuki Kato(Department of Sports Medicine, Kameda Medical Center)

[SP3-3]How to use CAR-T cell therapy in practice ? The past and the future from the view point of Cytotherapy Operation Science

^○Yasuyuki Arai(Kyoto University Hospital)

[SP3-4]Gene therapy for hereditary neuromuscular diseases in real clinical practice

^○Yuko Shimizu Motohashi(National Center of Neurology and Psychiatry)

[VSP-1]Identification of new targets for CAR-T cell therapy against hematological cancers

^○Naoki Hosen(Osaka University Graduate School of Medicine)

[VSP-2]Recent advances of CAR-T cell technology for the treatment of solid cancers

^○Koji Tamada(Yamaguchi University Graduate School of Medicine)

[VSP-3]Lights and shadows in CAR-T cell therapy - Expectation and exhaustion of the clinical team

^○Yasuyuki Arai(Kyoto University Hospital)

[VSP-4]Development of allogeneic iPSC-derived Regenerative CAR-T cell therapy

^○Shin Kaneko^1,2(1.Center for iPS cell Research and Application, Kyoto University, 2.Transborder Medical Research Center, University of Tsukuba)

[DB-1]ディベート

^○Ryosuke Takahashi(Graduate School of Medicine and Faculty of Medicine Kyoto University)

[DB-2]ディベート

^○Hideki Mochizuki(Department of Neurology, Osaka University Graduate School of Medicine)

[JS-1]Next generation gene therapies for Duchenne muscular dystrophy (DMD)

^○Jeffrey Scott Chamberlain, Hichem Tasafout(University of Washington School of Medicine)

[JS-2]How to empower current gene and cell therapy approaches by next generation AAV vectors

^○Hildegard Büning(Hannover Medical School, Hannover, Germany)

[JS-3]TBD

^○RYUICHI MORISHITA(Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University)

[IL1-1]TBD

^○Natalie Cartier(Askbio Biopharmaceuticals Therapeutics)

[IL2-1]Improving efficacy and safety of AAV vectors for in vivo gene therapy

^○Hildegard Büning(Hannover Medical School)

[IL3-1]Focal brain delivery of gene therapy via blood brain barrier opening in neurodegenerative diseases

^○JOSE A OBESO(Fundación HM Hospitales. Universidad CEU-San Pablo)

[IL4-1]A GENE THERAPY DELIVERED GROWTH FACTOR APPROACH TO TREATING PARKINSON’S DISEASE AND MULTIPLE SYSTEM ATROPHY

^○Adrian P Kells¹, Amber D Van Laar¹, Waldy San Sebastian¹, Massimo S Fiandaca¹, Krystof S Bankiewicz^1,2(1.Asklepios BioPharmaceutical, Inc. (AskBio), 2.The Ohio State University Wexner Medical Center)

[ED1-1]PMDA’s Vision for the Future

^○Haruko Yamamoto¹(1.National Cerebral and Cardiovascular Center, 2.Pharmaceuticals and Medical Devices Agency)

[ED2-1]What I think about as overviewing current gene therapy in Japan

^○Masafumi Onodera(Gene & Cell Therapy Promotion Center, National Center for Child Health and Development)

[ED3-1]Ethics and governance of human genome editing and gene therapy

^○Kazuto Kato(Osaka University, Graduate School of Medicine)

[ED4-1]TBD

^○Takanori Takebe(Osaka University)

[RM-1]Development of regeneration-inducing gene therapy for recessive dystrophic epidermolysis bullosa

^○Katsuto Tamai(Osaka University Graduate School of Medicine)

[RM-2]TBD

^○Yoshiki Sawa(Osaka Police Hospital)

[RM-3]Challenges for Stem Cell Gene Therapy for CNS Disorders

^○Hideyuki Okano(Department of Physiology, Keio University School of Medicine)

[RM-4]GAIA-NK: Its biological properties and current supply chain of PBMC sources

^○Yoshikazu Yonemitsu(Kyushu University Graduate School of Pharmaceutical Sciences)

[NA-1]Advancing Oligonucleotide Therapeutics: Unveiling a New Era of Precision Gene Medicines

^○Hideaki Sato(Luxna Biotech Co., Ltd.)

[NA-2]Development of Nucleic Acid Derivatives for Application to Antisense Oligonucleotides

^○Satoshi Obika¹(1.Graduate School of Pharmaceutical Sciences, Osaka University, 2.Institute for Open and Transdisciplinary Research Initiatives, Osaka University)

[NA-3]Development of intracellular environment-responsive lipid-like material (ssPalm) as a DDS platform for the acceleration of nucleic acid/RNA-based medication

^○Hidetaka Akita(Graduate School of Pharmaceutical Sciences、Tohoku University)

[NA-4]Exon skipping therapeutic strategy using 2'-O,4'-C-ethylene-bridged nucleic acid (ENA) oligonucleotides

^○Makoto Koizumi(Modality Research Laboratories, Daiichi Sankyo Co., Ltd.)

[JSV-1]Ex vivo gene-cell therapy using bornavirus vector

^○Ryo Komorizono¹, Shima Yoshizumi¹, Keizo Tomonaga^1,2,3(1.Lab. of RNA viruses, Institute for Life and Medical Sciences, Kyoto University, 2.Lab. of RNA Viruses, Graduate School of Biostudies, Kyoto University, 3.Department of Molecular Virology, Graduate School of Medicine, Kyoto University)

[JSV-2]Recent advances in the development of segmented double-stranded RNA virus vectors

^○Takeshi Kobayashi(Research Institute for Microbial Diseases, Osaka University)

[JSV-3]Molecular basis for the development of a novel LCMV vector capable of controlling foreign gene expression

^○Masaharu Iwasaki(Research Institute for Microbial Diseases, Osaka University)

[JSV-4]Generation of a photocontrollable recombinant bovine parainfluenza virus type 3

^○Takashi Okura¹, Maino Tahara¹, Noriyuki Otsuki¹, Moritoshi Sato^2,3, Kaoru Takeuchi⁴, Makoto Takeda⁵(1.Department of Virology 3, National Institute of Infectious Diseases, 2.Graduate School of Arts and Sciences, The University of Tokyo, 3.Kanagawa Institute of Industrial Science and Technology, 4.Laboratory of Environmental Microbiology, Faculty of Medicine, University of Tsukuba, 5.Graduate School of Medicine and Faculty of Medicine, The University of Tokyo)

[GE-1]Gene editing for gene therapy ~ Overview

^○Tsukasa Ohmori^1,2(1.Department of Biochemistry, Jichi Medical University, 2.Center for gene therapy research, Jichi Medical University)

[GE-2]Development of novel gene therapy via in vivo gene knock-in technology

^○Keiichiro Suzuki(Osaka University)

[GE-3]Development of gene therapy for Down syndrome using genome editing technology

^○Yasuji Kitabatake(Osaka University Graduate School of Medicine)

[GE-4]Induction of gigantic deletion and expansion of applicability to DMD by CRISPR-Cas3

^○Akitsu Hotta, Yuto Kita(CiRA, Kyoto University)